In the United States, Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, and Bexagliflozin are the five FDA-approved SGLT2 inhibitors for treating adults with type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.